Clinical Trial Results:
Measuring effects on pain and quality of life after Dysport® injection in children with cerebral palsy
Summary
|
|
EudraCT number |
2017-004497-33 |
Trial protocol |
DK |
Global end of trial date |
31 Dec 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Jan 2023
|
First version publication date |
20 Jan 2023
|
Other versions |
|
Summary report(s) |
article |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Protocol_Dysport_v3__13.12.2017
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
hvidovre hospital
|
||
Sponsor organisation address |
keettegaards alle 30, hvidovre, Denmark,
|
||
Public contact |
Christian Wong, Copenhagen University Hospital at Hvidovre, 0045 38626966, cwon0002@regionh.dk
|
||
Scientific contact |
Christian Wong, Copenhagen University Hospital at Hvidovre, 0045 38626966, cwon0002@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Dec 2021
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Oct 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Dec 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To examine the effect of botulinum toxin injections in regards to pain and quality of life in children with cerebral Palsy
|
||
Protection of trial subjects |
following rules of the EC
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jan 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 25
|
||
Worldwide total number of subjects |
25
|
||
EEA total number of subjects |
25
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
15
|
||
Adolescents (12-17 years) |
10
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
The subjects were paediatric patients with predominantly spastic CP and belonged to all gross motor function classification system (GMFCS) levels. They were recruited from our hospital service area as a convenience sample. Inclusion criteria were children between two and eighteen years of age with spastic cerebral palsy who were botulinum toxin naï | ||||||
Pre-assignment
|
|||||||
Screening details |
Children with CP in our general service area were screened for eligibility. Fifty-one of them had pain and were contacted through their caregivers for inclusion after a formal invitation by letter. After caregivers accepted participation, their medical records were screened according to the inclusion and exclusion criteria. If still eligible, the p | ||||||
Period 1
|
|||||||
Period 1 title |
Inclusion (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
No bilinding
|
||||||
Arms
|
|||||||
Arm title
|
followup | ||||||
Arm description |
Followup to 28 weeks | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Dysport
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution and suspension for suspension for injection in pre-filled syringe
|
||||||
Routes of administration |
Intramuscular use
|
||||||
Dosage and administration details |
A single ultrasound-guided intramuscular injection of AboA was administered without or under general anaesthesia by the discretion of the treating physician. Dosing was determined by the treating physician using 30 units per kilo (U/kg) and 15 U/kg for bilateral and unilateral CP, respectively, with a maximum dose of 1000 units. Small and large muscles were injected within a range of 3–6 U/kg and 8–12 U/kg, respectively. Small muscles were defined as an ultrasound-measured muscle thickness of a ‘diameter’ of less than 0.95 cm at the injection site and large muscles were defined as having a ‘diameter’ larger than 0.95 cm at the injection site [26,27]. Five hundred units of AboA were diluted in 2.5 mL of sterile NaCl in sterile syringes.
|
||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
followup
|
||
Reporting group description |
Followup to 28 weeks | ||
Subject analysis set title |
rflacc score
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
2.3. Assessments
The subjects were assessed with observational pain, questionnaires pertaining to pain, function, and quality of life at baseline before injection and after 4, 12, and 28 weeks. Our primary endpoint was the change in pain status from baseline to the initial follow up at four weeks since AboA is considered to have an optimal effect at this time [14]. The subjects were monitored continuously for adverse effects as well as changes in medication or therapeutic interventions.
2.4. Pain Tools
The observational pain tools of the Paediatric pain profile (PPP) and r-FLACC were utilized to captivate different aspects of localized pain. A systematic pain interview was carried out by a single rater.
2.4.1. Localized Muscular Pain Using the Revised Face, Legs Activity, Cry, Consolability Scale
Initial clinical evaluation entailed pROM of all muscles of the lower extremity to identify potential localized muscular pain using the r-FLACC. The r-FLACC scale is a validated behaviou
|
|
||||||||||||||||
End point title |
rflacc score | |||||||||||||||
End point description |
Localized Muscular Pain Using the Revised Face, Legs Activity, Cry, Consolability Scale
Initial clinical evaluation entailed pROM of all muscles of the lower extremity to identify potential localized muscular pain using the r-FLACC. The r-FLACC scale is a validated behavioural pain intensity tool with five categories with a three-point ordinal scale (0–2), thus ranging from 0 to 10 possible points. Each category entails a description of behavioural signs in the facial expression, legs, activity, cry and consolability [28]. The r-FLACC scores were evaluated during the examination and were videotaped systematically using two iPads, thus enabling us to re-evaluate the subject in the frontal and sagittal view [29]. The caregivers added a unique descriptive ‘pain’ behaviour of the child to ensure that our ratings were individual and accurate. The localized pain was evaluated for the treated muscles during the follow ups. Since injections of AboA are presumed to have a localized effect, ou
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
after 6 weeks
|
|||||||||||||||
|
||||||||||||||||
Notes [1] - all analyzed [2] - all analyzed |
||||||||||||||||
Statistical analysis title |
Statistical Analysis | |||||||||||||||
Statistical analysis description |
he overall comparisons were between the data at baseline and follow-ups. Shapiro–Wilk for normality was utilized to determine normal distribution. Data from r-FLACC, PPP, and CPCHILD scores were continuous variables and analysed using the paired t-test. Ordinal variables such as impact on activity and SMART goals were not normally distributed and analysed using the Wilcoxon signed-rank test. p-values of ≤0.05 were considered statistically significant. Bonferroni corrections were applied to the r
|
|||||||||||||||
Comparison groups |
followup v rflacc score
|
|||||||||||||||
Number of subjects included in analysis |
50
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
other [3] | |||||||||||||||
P-value |
≥ 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||
Point estimate |
3
|
|||||||||||||||
Confidence interval |
||||||||||||||||
level |
90% | |||||||||||||||
sides |
2-sided
|
|||||||||||||||
lower limit |
1 | |||||||||||||||
upper limit |
5 | |||||||||||||||
Variability estimate |
Standard error of the mean
|
|||||||||||||||
Dispersion value |
2
|
|||||||||||||||
Notes [3] - he overall comparisons were between the data at baseline and follow-ups. Shapiro–Wilk for normality was utilized to determine normal distribution. Data from r-FLACC, PPP, and CPCHILD scores were continuous variables and analysed using the paired t-test. Ordinal variables such as impact on activity and SMART goals were not normally distributed and analysed using the Wilcoxon signed-rank test. p-values of ≤0.05 were considered statistically significant. Bonferroni corrections were applied |
|
|||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
from 2018 to september 2021
|
||||||||||||||||||||||
Adverse event reporting additional description |
Eleven subjects experienced adverse events during the study. In total, there were sixteen adverse events. The majority were related (12). These were temporary mild (5) and moderate (1) muscle weakness, mild nausea (2), and mild soreness/local bruising (2) at the injection site. Two had moderate pain (2) at the injection site that subsided within th
|
||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
overnight stay | ||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
total number
|
||||||||||||||||||||||
Reporting group description |
Eleven subjects experienced adverse events during the study. In total, there were sixteen adverse events. The majority were related (12). These were temporary mild (5) and moderate (1) muscle weakness, mild nausea (2), and mild soreness/local bruising (2) at the injection site. Two had moderate pain (2) at the injection site that subsided within the first week. An additional three caregivers reported unrelated adverse events with weight gain (1), mild dyspnoea (1), and mild diarrhoea (1) during the study. At the study initiation, one subject (1) had an uneventful admission overnight since the ultrasound-guided injection of AboA was delivered close to an intramuscular vessel. This was classified as a serious adverse event. There was otherwise no expected or unexpected serious adverse events or reactions. | ||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Notes [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal. Justification: Eleven subjects experienced adverse events during the study. In total, there were sixteen adverse events. The majority were related (12). These were temporary mild (5) and moderate (1) muscle weakness, mild nausea (2), and mild soreness/local bruising (2) at the injection site. Two had moderate pain (2) at the injection site that subsided within the first week. An additional three caregivers reported unrelated adverse events with weight gain (1), mild dyspnoea (1), and mild diarrhoea (1) during |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/35051020 |